clinical trials
hope
Investigational Immunotherapy Trials
for Lung Cancer
The purpose of the Keynote lung cancer clinical trials is to see if the investigational drug, pembrolizumab, will slow down or stop the growth of lung cancer cells.
Pembrolizumab is an investigational immunotherapy that may help the body’s immune system attack cancer cells. When a cancer cell binds to an immune cell, the immune cell can’t do its job. These trials want to see if pembrolizumab can block cancer cells from binding with immune cells to help allow the immune cells to work properly.
For patients with non-small cell lung cancer (NSCLC)
Lung cancer occurs when cells inside the lung grow abnormally. As more cells grow, they start to form a tumor and may spread to other areas in the body. Non-small cell lung cancer is the most common type of lung cancer. Its sub-types include squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.
Depending on the stage of your cancer and other factors, treatment options for people with non-small cell lung cancer may include surgery, radiotherapy, chemotherapy or palliative care. Taking part in a clinical trial may also be an option for certain patients.
Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.
You can also call our clinical trial information center at 1-888-577-8839 to learn more.
22